Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 8/20 | 0.80 |
| ▸ | MAP3K7 | O43318 | 8/20 | 0.80 |
| ▸ | MAP2K1 | Q02750 | 5/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.80 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.80 |
| ▸ | HCK | P08631 | 1/20 | 0.74 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | CCNK | O75909 | 2/20 | 0.67 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.67 |
| ▸ | CDK2 | P24941 | 2/20 | 0.67 |
| ▸ | CCND3 | P30281 | 2/20 | 0.67 |
| ▸ | CDK9 | P50750 | 2/20 | 0.67 |
| ▸ | CDK6 | Q00534 | 2/20 | 0.67 |
| ▸ | BTK | Q06187 | 1/20 | 0.65 |
| ▸ | JAK3 | P52333 | 2/20 | 0.65 |
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | EGFR | P00533 | 1/20 | 0.63 |
| ▸ | BLK | P51451 | 1/20 | 0.63 |
| ▸ | BMX | P51813 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22807541 | 0.93 | SRC (0.80) | SRCMAP3K7MAP2K1MAPK1FGFR1 | |
| SCHEMBL28980988 | 0.93 | MAP3K7 (0.70) | SRCMAP3K7MAP2K1MAPK1FGFR1 | |
| SCHEMBL31684790 | 0.93 | MAP3K7 (0.70) | SRCMAP3K7MAP2K1MAPK1FGFR1 | |
| SCHEMBL22807482 | 0.91 | MAP3K7 (0.79) | SRCMAP3K7MAP2K1MAPK1FGFR1 | |
| SCHEMBL28981021 | 0.91 | SRC (0.67) | SRCMAP3K7MAP2K1MAPK1FGFR1 | |
| SCHEMBL22807446 | 0.91 | SRC (0.90) | SRCMAP3K7MAP2K1MAPK1FGFR1 | |
| SCHEMBL29549648 | 0.91 | SRC (0.90) | SRCMAP3K7MAP2K1MAPK1FGFR1 | |
| SCHEMBL28980966 | 0.90 | MAP3K7 (0.71) | SRCMAP3K7MAP2K1MAPK1FGFR1 | |
| SCHEMBL31684786 | 0.89 | SRC (1.00) | SRCMAP3K7MAP2K1MAPK1FGFR1 | |
| SCHEMBL22828520 | 0.89 | SRC (1.00) | SRCMAP3K7MAP2K1MAPK1FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4617261-A1 | 2,4,5-TRISUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wenzhou Medical University (CN) | 2025-09-17 | — | — | EP | claimed |
| CN-115894381-A | 2,4,5-trisubstituted pyrimidine compound and preparation method and application thereof | 温州医科大学 | 2023-04-04 | — | — | CN | claimed |
| EP-4617261-A1 | 2,4,5-TRISUBSTITUTED PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | Wenzhou Medical University (CN) | 2025-09-17 | — | — | EP | disclosed |
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| CN-115894381-B | 2,4, 5-Trisubstituted pyrimidine compound and preparation method and application thereof | 温州医科大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-115894381-A | 2,4,5-trisubstituted pyrimidine compound and preparation method and application thereof | 温州医科大学 | 2023-04-04 | — | — | CN | disclosed |
| US-20220267294-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-08-25 | — | — | US | disclosed |
| EP-3986411-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | Dana-Farber Cancer Institute, Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2020257385-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257385-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365664-B2 | Small molecule inhibitors of SRC tyrosine kinase | SRC, CTTN, LCK | SRC 1/4885MAP3K7 42/4885MAP2K1 1114/4885 |
| US-20220267294-A1 | SMALL MOLECULE INHIBITORS OF SRC TYROSINE KINASE | SRC, CTTN, LCK | SRC 1/4885MAP3K7 42/4885MAP2K1 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.